Table 3 Central nervous system (CNS) adverse events experienced by the 123 patients on EFV-based regimens reporting CNS symptoms prior to switch and change over time on RPV/TDF/FTC co-formulation
From: Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study
N (%) | |
|---|---|
CNS adverse events on previous EFV-based regimens | 197 (74 patients with > 1 symptoms) |
Insomnia/sleep disturbances | 53 (26.9%) |
Abnormal dreams | 37 (18.8%) |
Symptoms of depression | 34 (17.3%) |
Dizziness/vertigo | 30 (15.2%) |
Fatigue/tiredness | 27 (13.7%) |
Other | 16 (8.1%) |
Change in CNS symptoms reported by patients at 6 months after switch from EFV to RPV | 123 |
Worsening condition | 4 (3.3%) |
Stable condition | 18 (14.6%) |
Improved condition | 92 (74.8%) |
Other/unknown | 9 (7.3%) |
Further change in CNS symptoms at 12 months after switch from EFV to RPV in those who improved at M6 | 92 |
Worsening condition | 6 (6.5%) |
Stable condition | 72 (78.3%) |
Improved condition | 13 (14.1%) |
Other/unknown | 1 (1.1%) |